Diagnostic benefits of mindin as a prostate cancer biomarker

Background: It has been shown that decreased expression and activity of extracellular matrix protein mindin correlate with various types of cancers including breast, colon and lung cancers. The aim of the presented study was to investigate the serum mindin levels in prostate cancer. Methods: Mindin...

Full description

Bibliographic Details
Main Authors: Hanousková Lenka, Řezáč Jakub, Veselý Štěpán, Průša Richard, Kotaška Karel
Format: Article
Language:English
Published: Society of Medical Biochemists of Serbia, Belgrade 2020-01-01
Series:Journal of Medical Biochemistry
Subjects:
Online Access:https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2020/1452-82582001108H.pdf
Description
Summary:Background: It has been shown that decreased expression and activity of extracellular matrix protein mindin correlate with various types of cancers including breast, colon and lung cancers. The aim of the presented study was to investigate the serum mindin levels in prostate cancer. Methods: Mindin concentrations in serum were measured in 56 patients with prostate cancer (mean age 68 years) and in control group of 29 healthy men (mean age 64 years) using commercially available enzymatic immunoassay (Cusabio, WuHan, China). The patients were divided with respect to the severity of the disease into two groups according to the EAU guidelines (stage 1, 2 - less severe tumours, stage 3, 4 - severe tumours). Results: Serum mindin concentrations were significantly elevated in the group of healthy individuals unlike in the patients with prostate cancer (2.12 ng/mL vs 0.78 ng/mL, with P=0.0007, AUC=0.705). Patients with less severe tumours (stage 1, 2) and severe tumours (stage 3, 4) had significantly decreased levels of S-mindin as well (P=0.0037), although the difference in serum mindin concentrations between the patients with less severe and severe tumours was not significant. Conclusions: Concentrations of mindin were decreased in patients with prostate cancer and reduced in patients with less severe prostate cancer as well. Mindin appears to be a promising diagnostic marker useful in the diagnosis of prostate cancer.
ISSN:1452-8258
1452-8266